P
Peter J. Barnes
Researcher at National Institutes of Health
Publications - 1554
Citations - 177909
Peter J. Barnes is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Asthma & COPD. The author has an hindex of 194, co-authored 1530 publications receiving 166618 citations. Previous affiliations of Peter J. Barnes include University of Nebraska Medical Center & Novartis.
Papers
More filters
Journal ArticleDOI
Identifying Molecular Targets for New Drug Development for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?
TL;DR: A new promising approach is reversal of corticosteroid resistance through increasing histone deacetylase-2 activity, which might be achieved by existing treatments such as theophylline, nortriptyline, and macrolides, or more selectively by PI3kinase-δ inhibitors.
Journal ArticleDOI
Air pollutionand asthma: molecular mechanisms
TL;DR: The evidence that air pollutants (particularly sulphur dioxide, ozone and nitrogen dioxide) can affect the airways of asthmatic patients is reviewed, and the possible molecular mechanisms that may link air pollution to increased inflammation in the airway are discussed.
Journal ArticleDOI
Chronic systemic administration of salmeterol to rats promotes pulmonary β2‐adrenoceptor desensitization and down‐regulation of Gsα
Paul A. Finney,Louise E. Donnelly,Maria G. Belvisi,Tsu-Tshen Chuang,Mark A. Birrell,Andrew J. Harris,Judith C.W. Mak,Carol Scorer,Peter J. Barnes,Ian M. Adcock,Mark A. Giembycz +10 more
TL;DR: The results indicate that chronic treatment of rats with salmeterol results in heterologous desensitization of pulmonary Gs‐coupled receptors and it is proposed that a primary mechanism responsible for this effect is a reduction in membrane‐associated Gsα.
Journal ArticleDOI
Tumour Necrosis Factor α Causes Retention of Activated Glucocorticoid Receptor within the Cytoplasm of A549 Cells
TL;DR: The results suggest that a major site of pro-inflammatory cytokine action may be within the cytoplasm of steroid-responsive cells acting via prevention of the GR translocation into the nucleus.
Journal ArticleDOI
Anti-IgE antibody therapy for asthma.
TL;DR: Antileukotrienes are the only new class of drugs to treat asthma that have been introduced in the past 25 years, but their efficacy is somewhat limited and unpredictable, as compared with that of inhaled corticosteroids.